Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) EBIT Margin (2016 - 2025)

Enanta Pharmaceuticals' EBIT Margin history spans 14 years, with the latest figure at 60.45% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 7837.0% year-over-year to 60.45%; the TTM value through Dec 2025 reached 109.08%, up 5663.0%, while the annual FY2025 figure was 130.65%, 4927.0% up from the prior year.
  • EBIT Margin reached 60.45% in Q4 2025 per ENTA's latest filing, up from 121.56% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 60.45% in Q4 2025 to a low of 221.7% in Q1 2023.
  • Average EBIT Margin over 5 years is 152.93%, with a median of 152.03% recorded in 2021.
  • Peak YoY movement for EBIT Margin: tumbled -10453bps in 2021, then surged 8282bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 109.99% in 2021, then dropped by -16bps to 127.25% in 2022, then tumbled by -52bps to 193.78% in 2023, then increased by 28bps to 138.82% in 2024, then soared by 56bps to 60.45% in 2025.
  • Per Business Quant, the three most recent readings for ENTA's EBIT Margin are 60.45% (Q4 2025), 121.56% (Q3 2025), and 103.16% (Q2 2025).